Cambrios lands $14.5M for electronic display components
Cambrios, maker of conductive films used in electronic displays and monitors, has brought in $14.5 million in a fourth round of venture capital. Based in Sunnyvale, Calif., the company is backed by ARCH Venture Partners, Alexandria Real Estate Equities, Alloy Ventures, Altitude Life Science Ventures, Avalon Ventures, Harris & Harris Group, Headland Ventures, In-Q-Tel, Kidron, Lux Capital, Mitsubishi UFJ Capital, Oxford Bioscience Partners, Presidio Ventures, Sumitomo, Chisso and Nissha Printing.
Limerick BioPharma raises $1.5M to limit drug side effects
Limerick BioPharma, a South San Francisco firm specializing in drugs that curb the side effects of other drugs, has brought in $1.5 million in debt, rights and securities that it plans to use as working capital, according to VentureWire. Formerly called Limerick Neurosciences, the company says its products minimize the toxic impact some drugs can have on organs that they aren’t targeting — making more medications safer for a wider range of people. So far,… Continue Reading
Arete nabs $16.7M more to treat metabolic disorders
Biotech company Arete Therapeutics brought in $16.7 million in the final tranche of a first round of funding that now totals $51 million. The Hayward, Calif.-based company will use the money to push its lead treatment for metabolic syndrome through a second phase of clinical trials. It also develops drugs for inflammatory and cardiovascular diseases, focusing on an enzyme that breaks down arachidonic acid (a critical component of those ailments).
The financing round has… Continue Reading
Arete raises $35M for cardiovascular treatments
Arete Therapeutics, a Hayward, Calif., developer of biotech cardiovascular treatments, raised a $35 million extension to its first round of funding. Founded in 2003, the company is working on “small molecule” drugs that target a metabolism-related chain of biochemical cellular signals that involves arachidonic acid. (If that isn’t enough to make your head hurt, the company has a detailed explanation here.) Drugs that interfere with that pathway could be useful in treating high blood pressure… Continue Reading